Effect of Age on the Success of DPC Using Bio-ceramic Materials in Cariously Exposed Teeth With Reversible Pulpitis

Effect of Age on the Success of Direct Pulp Capping Using Bio-ceramic Materials in Cariously Exposed Teeth With Reversible Pulpitis: A Prospective Clinical Study.

Study Title: - Effect of age on the success of direct pulp capping using bio-ceramic materials in cariously exposed teeth with reversible pulpitis: A Prospective clinical study.

Rationale: - Preservation of pulp vitality is a critical factor in long-term tooth survival. In deep carious lesion with reversible pulpitis, vital pulp therapy procedures in the form of direct pulp capping(DPC)is more conservative treatment strategy, based on the premise that a biologically active material placed in direct contact with the pulp wound can determine the pulpal response and result in the development of a reparative hard tissue bridge to preserve pulp vitality. Patient's age may have a role in the survival rate after direct pulp capping and the role of the pulp capping material has been recognized as an important parameter for the success of treatment.

Research Question : Does age has any influence on the success of DPC procedure and is there any difference between MTA and Biodentine as DPC material in cariously exposed permanent teeth with reversible pulpitis? Aim & Objectives- To evaluate the effect of age on success of Direct Pulp Capping, to evaluate the success of MTA and Biodentine as direct pulp capping agents.

Study Overview

Detailed Description

Study Title: - Effect of age on the success of direct pulp capping using bio-ceramic materials in cariously exposed teeth with reversible pulpitis: A Prospective clinical study.

Rationale: - Preservation of pulp vitality is a critical factor in long-term tooth survival. In deep carious lesion with reversible pulpitis, vital pulp therapy procedures in the form of direct pulp capping(DPC)is more conservative treatment strategy, based on the premise that a biologically active material placed in direct contact with the pulp wound can determine the pulpal response and result in the development of a reparative hard tissue bridge to preserve pulp vitality. Patient's age may have a role in the survival rate after direct pulp capping and the role of the pulp capping material has been recognized as an important parameter for the success of treatment.

Research Question : Does age has any influence on the success of DPC procedure and is there any difference between MTA and Biodentine as DPC material in cariously exposed permanent teeth with reversible pulpitis? Aim & Objectives- To evaluate the effect of age on success of Direct Pulp Capping, to evaluate the success of MTA and Biodentine as direct pulp capping agents based on clinical and radiographic findings and assessment of post operative pain for 7 days post treatment.

Statistical method: - Data analysis by suitable statistical method.

Study Type

Interventional

Enrollment (Actual)

174

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

    • Haryana
      • Rohtak, Haryana, India, 124001
        • PGIDS

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

  • Adult

Accepts Healthy Volunteers

Yes

Description

Inclusion Criteria:

  • Healthy patients (ASA I and ASA II).
  • Patients falling in the age group of 18-60 years.
  • Restorable permanent mandibular posterior teeth.
  • Extremely deep caries penetrating the entire thickness of dentine and exhibiting signs and symptoms of reversible pulpitis.
  • Teeth responding positively to cold test and electric pulp testing with no tenderness on percussion.

Exclusion Criteria:

  • Primary teeth.
  • Traumatic or mechanical exposure.
  • No pulp exposure after caries excavation.
  • Hemostasis not achieved within 10 mins.
  • Teeth with irreversible pulpitis.
  • Presence of periapical lesion or evidence of internal or external resorption, calcified canals, as assessed by radiographic examination.
  • Patients with periodontal disease, swelling and sinus tract.
  • Immunocompromised or pregnant patients, patients with any systemic disease, and a positive history of antibiotic use within 1 month and analgesic use within week before the treatment.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: Non-Randomized
  • Interventional Model: Parallel Assignment
  • Masking: Double

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: DPC in AGE I with MTA
DPC using MTA in Age group I i.e. 18-40years.
DPC using MTA in 18-40 years
Experimental: DPC in AGE I with BD
DPC using BD in Age group I i.e. 18-40years.
DPC using BD in 18-40 years
Experimental: DPC in AGE II with MTA
DPC using MTA in Age group II i.e. 41-60years
DPC using MTA in 41-60Years
Experimental: DPC in AGE II with BD
DPC using BD in Age group II i.e. 41-60years
DPC using BD in 41-60Years

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
clinical and radiographic success rates and evaluation of the effect of age on the success of procedure.
Time Frame: Baseline to 18 months

CLINICAL SUCCESS CRITERIA

  • Absence of sign and symptoms of pain on stimulus or spontaneous pain.
  • Absence of tenderness to palpation or percussion and presence of functional tooth.
  • Absence of any soft tissue swelling sinus or fistula.
  • Normal tooth mobility and no periodontal probing depth.
  • Positive response to pulp sensibility test (cold and EPT).

RADIOGRAPHIC SUCCESS CRITERIA

  • Periapical Index (PAI) score ≤2.
  • Absence of external or internal root resorption.

Also, to evaluate the effect of age on the success of procedure.

Baseline to 18 months

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Post operative pain Secondary outcome measure will be pain intensity after treatment. Secondary outcome measure will be pain intensity after treatment. Secondary outcome measure will be pain intensity after treatment.
Time Frame: Base line to 7 days
To assess incidence and intensity of pain postoperatively at every 24 hours till 7 days using Visual analogue Scale of 0 to 100 millimeter line. Score 0 means no pain and Score 100 means maximum pain To assess incidence and intensity of pain postoperatively at every 24 hours till 7 days using Visual analogue Scale of 0 to 100 millimeter line. Score 0 means no pain and Score 100 means maximum pain
Base line to 7 days

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Investigators

  • Principal Investigator: Sanjay Tewari, Pgids Rohtak

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

June 1, 2022

Primary Completion (Actual)

March 30, 2023

Study Completion (Estimated)

March 30, 2024

Study Registration Dates

First Submitted

January 14, 2024

First Submitted That Met QC Criteria

January 26, 2024

First Posted (Actual)

February 2, 2024

Study Record Updates

Last Update Posted (Actual)

February 2, 2024

Last Update Submitted That Met QC Criteria

January 26, 2024

Last Verified

January 1, 2024

More Information

Terms related to this study

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

product manufactured in and exported from the U.S.

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Pulpitis Reversible

Clinical Trials on DPC with MTA in AGEI

3
Subscribe